Standout Papers

Recommendations for management of patients with neuroendocrine liver metastases 2014 2026 2018 2022 339
  1. Recommendations for management of patients with neuroendocrine liver metastases (2014)
    Andrea Frilling, Irvin M. Modlin et al. The Lancet Oncology

Immediate Impact

1 from Science/Nature 56 standout
Sub-graph 1 of 23

Citing Papers

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
3 intermediate papers

Works of Christopher Russell being referenced

Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease
2021
Recommendations for management of patients with neuroendocrine liver metastases
2014 Standout

Author Peers

Author Last Decade Papers Cites
Christopher Russell 187 194 115 418 347 28 709
Jennifer R. Eads 175 148 91 585 321 47 778
A Autret 334 264 68 465 283 43 757
D.G. Haller 285 176 91 531 170 28 791
Mi Kyung Bae 462 201 139 288 136 29 805
İ. Çeli̇k 73 59 191 320 222 29 686
Ulrich Stölzel 173 113 218 330 153 30 769
Marta Llanos 103 68 84 437 260 44 745
P. Ruszniewski 65 334 179 359 454 51 841
Nathalie Théou–Anton 312 78 125 358 132 28 649
Laura Tang 90 152 41 481 507 15 768

All Works

Loading papers...

Rankless by CCL
2026